Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Cloud Computing ETF (CLOU) vs Eli Lilly And Co (LLY) Price & Performance

Global X Cloud Computing ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global X Cloud Computing ETF vs Eli Lilly And Co — how do they compare? Global X Cloud Computing ETF trades at $27.69, while Eli Lilly And Co trades at $1,215 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while Global X Cloud Computing ETF pays none. Which is the better fit depends on your goals.

CLOULLY
Sector
Sector/ThematicHealth
52-Week High
$28.09$1.24K
52-Week Low
$17.60$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cloud Computing ETF

CLOU, the Global X Cloud Computing ETF, trades at $27.83, down 0.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides diversified exposure to cloud computing stocks, with top holdings like Snowflake and Datadog showing strong non-AI growth drivers. Recent news highlights long-term growth potential beyond AI hype, supported by customer expansion and resilient subscription revenues.

Outlook remains positive for long-term investors due to structural growth in cloud adoption, though short-term risks include high valuations and sector volatility. Key opportunities lie in business diversification and profitability improvements among holdings, while risks involve competitive pressures and macroeconomic sensitivity affecting tech stocks.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Cloud Computing ETF

CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.

Read more on CLOU

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY